Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

Publication | Closed Access

DOI

689

Citations

References

2015

Year

Cornelia L. Trimble, Matthew P. Morrow, Kimberly A. Kraynyak, Xuefei Shen, Michael Dallas, Jian Yan, Lance Edwards, Raphaëlle Parker, Lynette Denny, Mary Giffear,

The Lancet

ImmunologyHuman Papillomavirus 16Cancer-associated VirusCervical Cancer PreventionHuman Papillomavirus VaccinesVaccine TargetPlacebo-controlled Phase 2BPublic HealthRadiation OncologyCervical HealthTherapeutic VaccinePolyvalent VaccineVaccinationCervical Cancer ManagementCervical Cancer ScreeningCervical CancerE7 ProteinsMedicineVaccine ResearchPrecancerous Lesions